Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) is advancing its mission to improve cardiovascular disease prevention and early detection through precision medicine, as highlighted by CEO and Co-Founder Dr. Meesha Dogan in a recent episode of The BioMedWire Podcast. Dogan detailed the company's expansion into India via partnerships with Aimil Ltd. and Dr. Lal PathLabs, as well as its progress through the Medicare reimbursement process.
The company, which leverages epigenetics, genetics, and artificial intelligence, is focused on making cardiovascular disease management more accessible and personalized. According to Dogan, Cardio Diagnostics has completed CPT coding and payment steps for Medicare, with coverage determination still underway. This milestone is critical for the company's commercial strategy, as it could expand patient access to its AI-driven tests.
The India expansion represents a significant market opportunity. By partnering with Aimil Ltd. and Dr. Lal PathLabs, Cardio Diagnostics aims to tap into a large population with growing cardiovascular disease prevalence. These partnerships are expected to facilitate distribution and clinical validation in the region.
Cardio Diagnostics' core technology, an AI-driven Integrated Genetic-Epigenetic Engine, forms the basis for its clinical tests. The company aims to become a leading medtech player in cardiovascular disease prevention, detection, and treatment. The precision medicine approach could shift the paradigm from reactive treatment to proactive prevention, potentially reducing healthcare costs and improving patient outcomes.
The news matters because cardiovascular disease remains the leading cause of death globally. Cardio Diagnostics' efforts to secure Medicare coverage and expand internationally could broaden access to advanced diagnostic tools. If successful, the company's tests may enable earlier intervention, which is key to reducing mortality and morbidity. For investors, the progress in reimbursement and market expansion signals potential revenue growth and competitive advantage in the precision medicine space.
Listeners can access the full podcast episode for more details on the company's strategy. For ongoing updates, Cardio Diagnostics maintains a newsroom at https://ibn.fm/CDIO.
